Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Juan, PR
NPI
1316092208
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
Repto Metropolitano
San Juan, PR, 00926
Phone (787) 474-7346
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
322 services
Medicare patients, 2024
150
Average age 77
Drug cost, 2024
$5.5M
15,166 prescriptions
Company payments, 2025
$15K
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manuel Alegre-Hernandez was code 99214 (office e&m - established), 208 times for 120 patients. In total Manuel Alegre-Hernandez billed 322 services in 6 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-03-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 208 | 120 | $80.86 | $17K |
| 99213 Office E&M - Established | Office | 85 | 57 | $59.64 | $5,069 |
| 99204 Office E&M - New | Office | 18 | 18 | $102.93 | $1,853 |
By year: 2022 $26K for 428 services; 2023 $25K for 353 services; 2024 $24K for 322 services.
Medicare prescription drug claims, 2024
In 2024, the drug Manuel Alegre-Hernandez prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 2,617 prescriptions and refills. In total Manuel Alegre-Hernandez wrote 15,166 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 2,617 | 6,814 | 860 | $313K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 867 | 1,607 | 229 | $966K |
| Trulicity Dulaglutide | 792 | 825 | 108 | $815K |
| Lantus Insulin Glargine,hum.Rec.Anlog | 732 | 861 | 162 | $70K |
| Rosuvastatin Calcium Generic | 705 | 2,039 | 300 | $14K |
| Jardiance Empagliflozin | 691 | 1,267 | 215 | $765K |
| Ozempic Semaglutide | 545 | 570 | 96 | $559K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 521 | 814 | 129 | $57K |
| Metformin Hcl Generic | 485 | 1,331 | 196 | $4,085 |
| Humalog Kwikpen U-100 Insulin Lispro | 384 | 482 | 93 | $72K |
| Losartan Potassium Generic | 326 | 907 | 128 | $4,954 |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | 323 | 649 | 91 | $382K |
| Humalog Insulin Lispro | 299 | 332 | 69 | $31K |
| Omega-3 Acid Ethyl Esters Generic | 298 | 819 | 132 | $40K |
| Simvastatin Generic | 251 | 701 | 106 | $2,782 |
Brand drugs: 9,478 claims; generic drugs: 5,296 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manuel Alegre-Hernandez $15K ($15K in general payments such as food, travel and fees) from 5 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $13K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.